Skip to main
TMO
TMO logo

TMO Stock Forecast & Price Target

TMO Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 25%
Buy 63%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Thermo Fisher Scientific is projected to achieve a compound annual growth rate (CAGR) of 5.4% in its lab products and services segment over the next three years, despite a notable decline from the previous growth rate of 16.9% from 2019 to 2024. The company is expected to gain market share in the contract research organization (CRO) sector, driven by an impressive solution set and favorable biopharma clinical trial outsourcing trends, with significant increases anticipated in outsourcing for both early-stage and late-stage drug development. Additionally, revenue from analytical instruments is forecasted to grow at a CAGR of 2.5%, reflecting a more moderate but steady contribution compared to the previous growth rate of 6.2% from 2019 to 2024.

Bears say

Thermo Fisher Scientific has experienced a significant decline in its financial performance from 2021 to 2024, with adjusted EBIT margin decreasing by approximately 830 basis points to 22.6%. Additionally, the firm has faced a steep drop in adjusted gross margin, which fell by around 940 basis points to 42.2%, underperforming relative to the 46.4% gross margin recorded in 2019. This downward trend in profitability metrics raises concerns regarding the company's overall financial health and future growth prospects.

TMO has been analyzed by 16 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 63% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Thermo Fisher Scientific (TMO) Forecast

Analysts have given TMO a Buy based on their latest research and market trends.

According to 16 analysts, TMO has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $611.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $611.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Thermo Fisher Scientific (TMO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.